MedTech Startup: The Definitive Guide for Founders and Board Members

Three out of four medtech startups fail. Not because their technology doesn't work—most have sound science. They fail because they get the sequence wrong: building before validating, submitting before strategizing, fundraising before de-risking. The gap between a promising concept and a successful commercial product is filled with regulatory hurdles, funding challenges, and operational complexities that humble even experienced entrepreneurs.

I wrote this for founders (and board members) who probably have a solid foundation in one area like technology or med device sales, but need a map through the remaining complex terrain that separates a promising concept from a product on the market. Along the way, I'll link to deeper resources on specific topics and share lessons from companies that got it right—and those that didn't.

How to Start a MedTech Startup: The Right Sequence

If you're wondering how to start a medtech startup, the answer is deceptively simple: get the sequence right. Before writing a line of code or machining a prototype, you need to (1) validate that your target customers will commit—not just praise—your solution, (2) determine your regulatory pathway based on the claims you intend to make, (3) estimate the capital required to reach each major milestone, and (4) assemble a team that covers the critical gaps between your technical vision and commercial reality.

The MedTech Startup Landscape in 2026

Market Size and Growth Trajectory

The global medical technology market reached $694.7 billion in 2025 (MarketsandMarkets), with the U.S. commanding roughly 45% of that share. The industry continues to grow at approximately 5.5% CAGR, driven by aging populations, chronic disease prevalence, and technological innovation. By 2030, the global market is projected to exceed $800 billion.

The hottest sectors attracting capital include:

• Surgical robotics (20% CAGR) - Precision surgery and minimally invasive procedures. Intuitive Surgical's da Vinci dominance is finally facing credible challenges.
• Cardiovascular devices - The largest device category by revenue, with structural heart and electrophysiology driving growth.
• AI-enabled diagnostics - Software as a Medical Device (SaMD) is reshaping how we detect disease, from radiology to pathology to cardiac monitoring.
• Wearable devices - Continuous monitoring moving from hospital to home, enabled by improved sensors and connectivity.
• Neuromodulation - Electrical stimulation therapies expanding beyond pain management into mental health and metabolic disease.
• Remote patient monitoring - Post-COVID acceleration of care delivery outside traditional clinical settings.

Within each segment, the competitive landscape varies dramatically. Some areas (like commodity diagnostic testing) are crowded and price-competitive. Others (like novel neurological therapies) have significant white space but require extensive clinical development. Choosing where to compete is one of the most consequential decisions a founder makes, yet many founders land in their market by happenstance rather than by design.

Investment Climate and Funding Realities

The venture capital environment has shifted dramatically since 2022. According to J.P. Morgan's Q1 2025 medtech report, Q1 2025 saw $3.7 billion raised across 117 rounds—a 9% year-over-year increase that signals cautious optimism. However, the "flight to quality" means investors are more selective than ever.

What that looks like in practice:

• 65% of capital now flows to Series B and later-stage companies
• Seed and Series A rounds totaled $1.9 billion with a median round of $3.5 million
• AI-driven mega-rounds are capturing outsized attention and capital
• Investors demand more de-risking before committing

Full-year 2025 confirmed the recovery: $14.2 billion in digital health funding across 482 deals—a 35% increase over 2024—alongside $97.6 billion in medtech M&A and 13 IPOs raising over $8.5 billion combined. Mega-deals ($100M+) accounted for 42% of all funding, reinforcing what founders already feel on the ground: later-stage, de-risked companies are capturing most of the capital.

For detailed data on deal activity and funding trends, see MedTech Venture, Partnership, and M&A Trends. For practical strategies, see Fundraising in a Difficult Capital Raising Environment.

Why Most MedTech Startups Fail

Startups ultimately fail for two reasons: they're out of funds or out of hope. In MedTech, they're usually put on that path by decisions (or omissions) made much earlier.

Regulatory and Compliance Pitfalls

The FDA is your first customer. If you can't get past regulatory clearance, you can't sell. Yet many founders treat regulatory strategy as an afterthought.

The regulatory failures I see most often:

• Assuming you don't need FDA clearance - Many founders wrongly believe their device falls outside FDA jurisdiction. The related myth—"we can always pivot to wellness if FDA is too hard"—is equally dangerous. The wellness pathway is narrower than most founders believe. If your device monitors health conditions, provides alerts, or could reasonably be used to make medical decisions, the FDA will likely consider it a medical device regardless of how you market it. The Owlet case study demonstrated this clearly.
• Defaulting to 510(k) - Sometimes De Novo or even PMA is actually your best path. De Novo may actually be faster for truly novel devices, and creates a classification that others must reference. Some companies waste months searching for a predicate that doesn't exist when De Novo would have been more efficient from the start.
• "We'll figure out FDA later" - Regulatory strategy should be determined before significant R&D investment. Your claims determine your pathway, your pathway determines your evidence requirements, and your evidence requirements determine your budget and timeline. Figuring it out later means expensive rework—or discovering your business model doesn't work.
• Conducting unusable clinical studies - Studies designed for academic publication often can't support FDA submissions. And no amount of technical innovation exempts you from evidence requirements. Novel technologies often require more clinical data, not less, because there's no predicate to lean on.

As regulatory expert Ery Anguiano explains in Regulatory Due Diligence 101, "Claims come first. What you claim determines your pathway, your evidence burden, your timeline, and your capital requirements."

Funding and Financial Missteps

Medtech development cycles are long—typically 3-7 years from concept to commercial product. Running out of runway before reaching your next milestone is a death sentence.

The financial mistakes that kill companies:

• Underestimating capital requirements - Bringing a 510(k) device from concept to market costs an average of $31 million (77% on regulatory activities); PMA devices average $94 million
• Misaligned investor expectations - Consumer tech investors often don't understand medtech timelines
• Burning cash on the wrong priorities - Building before validating market demand wastes precious runway
• Not controlling time - Medtech startups typically have no revenue until they enter the commercial phase, so it's critical that time, like money, be budgeted like a limited resource.

For a framework on assessing your financial constraints, see Diagnosing a MedTech Startup.

Market and Commercial Blind Spots

A technically excellent device that nobody buys is still a failure.

• Insufficient market validation - Customer praise is not the same as customer commitment. When potential customers say "that's amazing, I would definitely use that," it doesn't count as validation until they actually commit.
• Confusing physician enthusiasm for commercial traction - Hospital purchasing involves administrators, value analysis committees, supply chain, and often group purchasing organizations (GPOs). A physician champion helps, but the economic buyer may be someone who never touches patients.
• Reimbursement complexity - If payers won't cover your device, hospitals won't buy it. And don't assume FDA clearance means the hard part is over—regulatory clearance is the beginning of commercialization, not the end. Manufacturing scale-up, reimbursement coding, hospital contracting, sales force development, and clinical training all remain.
• Adoption resistance - Clinicians prefer their established workflows; see The Three Overlooked Seeds of Innovation Adoption DNA
• Underestimating sales cycles - Healthcare enterprise sales take 6-12 months, not weeks

As Victoria Lahutskaya details in Five Mistakes I Made Building a Healthcare Startup, these commercial blind spots are often the most painful because they emerge late—after significant capital has been spent on development.

Leadership and Expertise Gaps

Early-stage medtech companies often have heavy R&D focus but lack commercial, regulatory, or operational expertise. The wrong team composition—or the wrong hires—can doom a company.

• Hiring for resume over agency - Early-stage startups need doers, not delegators. Controlling the timeline requires more than smarts and experience; it requires diligent execution against an objective.
• Missing critical expertise - Regulatory affairs, quality, clinical, and commercial leadership are all essential to deliver a regulatory submission that will achieve approval.
• Founder blind spots - Technical founders may not recognize their own gaps in business acumen; commercial-side founders might not see their technical gaps. The founder or CEO needs advisors to help balance out their focus.

The Regulatory Roadmap: FDA, EU MDR, and Beyond

The single most common mistake Ery Anguiano noted in Regulatory Due Diligence 101 is founders who build first and ask the FDA second. Regulatory strategy determines your timeline, your capital requirements, and ultimately whether your company survives.

Understanding FDA Device Classification

Most founders know the FDA classifies devices into three risk categories — Class I (low risk, general controls), Class II (moderate risk, 510(k) clearance), and Class III (high risk, PMA). What they don't know — and what costs them time — is that classification isn't just about risk. It determines your evidence burden, your timeline, and your fundraising math. A Class II device with a clear predicate might cost you $31M and two years. A Class III device requiring a PMA could mean $94M and five-plus years. That's not a rounding error — it's a completely different company.

Choosing the Right Pathway: 510(k) vs. De Novo vs. PMA

You can't drive to the airport, board a plane of your choice and then decide where it's going. It's the same in MedTech. You can't choose what product you build and then pick the regulatory pathway for it. Your path to FDA clearance depends on your product, and possibly on whether another company has released a similar product.

Your regulatory path has huge implications for the cost and difficulty of bringing your product to market. It's a strategic consideration that needs to happen before you even start raising money.

510(k) Clearance

• Demonstrate "substantial equivalence" to a legally marketed predicate device
• FDA review goal: 90 days. Actual average: ~140 days (calendar time from submission to decision)
• Average total cost from concept to market: $31 million
• Best for: Devices similar to existing products

De Novo Classification

• For novel, low-to-moderate risk devices without a predicate
• FDA review goal: 150 days. Actual average: 290-310 days
• Creates a new classification that others can use as a predicate
• Best for: Innovative devices that don't fit existing classifications

Premarket Approval (PMA)

• Most stringent pathway for Class III devices
• Requires clinical trials demonstrating safety and effectiveness
• Average cost: $94 million (80% FDA-linked activities)
• FDA review goal: 180 days without advisory committee, 320 days with. Actual average: ~290 days for review alone; total timeline typically 1-3 years including clinical trials
• Best for: Life-sustaining, life-supporting, or implantable devices

Product Roadmapping Strategy

Planning your product roadmap might seem silly when you're a shiny new startup, yet it can have practical and strategic value.

For instance, Ery Anguiano suggests thinking in terms of product versions, not just a single device. The same core technology can support different claim levels:

1. V1: Monitoring - Measure and display data (lower risk, faster to market)
2. V2: Alerting - Add thresholds and notifications (moderate risk)
3. V3: Diagnostic - Make or support clinical decisions (higher risk, higher value)

This staged approach lets you generate revenue and real-world data while building toward higher-value claims. For more on prioritizing development work, see From Idea to Impact: Prioritizing in Early MedTech R&D.

If a claim hierarchy doesn't apply to your product, you can also divide your product into stages. You can build an early prototype for fundraising, followed by a manufacturable prototype you can evolve into a device suitable for a human trial.

As the device enters trials, you can in parallel work on a commercial product based on what you learn in the trial.

The core idea of roadmapping is that you de-risk your business early, take smaller bets, and ideally arrive at revenue earlier.

EU MDR Compliance Essentials

If you're targeting European markets, the EU Medical Device Regulation (MDR) is a separate planning exercise with its own timeline pressures. Notified Body capacity remains constrained, CE marking requirements are more stringent than the old MDD framework, and post-market surveillance obligations have increased. The EU adopted targeted amendments in December 2025 that extend transition timelines and simplify certain conformity assessment procedures — welcome relief, but plan conservatively, because implementation is still unfolding. If you're building a U.S.-first strategy, don't treat EU MDR as an afterthought — the clinical evidence and quality system requirements overlap enough that early planning saves you from expensive rework later.

Quality Management Systems

The idea of a Quality Management System (QMS) is to demonstrate that you have control over your development process. Regulators want to see that you've designed your product, built your manufacturing process, and run your business in a way that's rational, repeatable, and systematically controls for risks to patients.

Here are the standards that matter:

• ISO 13485 - The international standard for medical device quality management
• FDA QMSR - The FDA's Quality Management System Regulation, now in effect as of February 2, 2026, harmonizing FDA requirements with ISO 13485
• ISO 14971 - Risk management throughout the product lifecycle
• Design controls - Documented design and development process required by FDA

Many founders view the QMS as bureaucratic overhead. This is a mistake. A well-designed QMS actually accelerates development by catching problems early, providing clear documentation for regulatory submissions, and creating institutional knowledge that survives personnel changes.

The companies that struggle with FDA submissions are often those that tried to retrofit quality documentation after the fact. The same applies to cybersecurity—the FDA now requires 14 cybersecurity artifacts for any device with software, and bolting them on late is far more expensive than building them in from the start.

The design and implementation of your QMS is critical; these systems are seen as bureaucratic because so many are poorly-designed, written with verbose language, and rely on byzantine software. As you design your QMS, ensure that you're not signing your team up for more administrative work than necessary. You want your team delivering results, not wasting hours formatting documents, creating redlines, and fighting software to update a report.

AI and Machine Learning Considerations

AI is a hot topic in every field. Because the results of AI algorithms are often based on training rather than programming, the regulatory approach is different and evolving. If your device incorporates AI or machine learning, additional regulatory considerations apply:

• Software as Medical Device (SaMD) - The FDA has specific guidance for software-based diagnostic and therapeutic tools
• Predetermined Change Control Plan (PCCP) - For ML algorithms that learn and update, FDA now offers a pathway for pre-approved modifications
• Algorithm transparency - Regulators increasingly want to understand how your AI reaches its conclusions
• Training data requirements - Documentation of datasets used to train algorithms, including diversity and representativeness

The FDA's Digital Health Center of Excellence has become more sophisticated in evaluating AI-based devices. If you're building in this space, engage early through pre-submission meetings to align on expectations. Beyond regulatory considerations, AI introduces governance challenges around intellectual property and employee use that boards need to address; see The AI Governance Gap. For a practical framework on adopting AI tools internally without drowning in infrastructure, see Adopting AI Internally.

Reimbursement Strategy

In most businesses, your customer pays you directly. In healthcare, a chain of payers stands between you and revenue — insurance, Medicare, hospital procurement. Regulatory clearance gets you permission to sell. Reimbursement gets you paid. Many technically excellent devices have failed commercially because founders didn't plan for payer dynamics, and scaling your business means finding or creating a path through that chain.

The concepts you need to understand:

• CPT codes - Current Procedural Terminology codes that define billable procedures. Maintained by the AMA, these codes are how physicians and hospitals get paid for using your device.
• Coverage determination - Whether Medicare and private payers will pay for your device. CMS issues national coverage determinations (NCDs) and local Medicare contractors issue local coverage determinations (LCDs).
• Health Technology Assessment (HTA) - Formal evaluation of clinical and economic value, increasingly required in EU markets under the EU's HTA Regulation.
• Budget impact analysis - How your device affects overall healthcare costs — often required by payers and HTA bodies to justify coverage.

The reimbursement timeline trap: New CPT codes are reviewed by the AMA's CPT Editorial Panel, which meets three times per year. Approved codes typically take effect the following January. If you miss a submission cycle, you may wait months for the next panel meeting — and then months more for implementation. Many companies don't realize this until too late.

For devices without existing coding, you may need to pursue a Coverage with Evidence Development (CED) pathway with CMS, which requires additional clinical data collection. Plan for this in your clinical trial design if relevant.

Manufacturing Readiness

Your prototype is not your product. Even the device you use in Clinical Trials might not have the economic characteristics to support scaling to many patients. The gap between a working prototype and a manufacturable, reliable device has humbled many engineering teams.

Here's what I tell startups over and over: reality is the best simulator. While you can learn many things before a device touches patients, you will learn things you've never dreamed of when you start using your device in a real clinical setting.

Your clinicians will misunderstand instructions. Your patients will interact with the system in their own unique way. Every aspect of your product will experience new physical interactions.

The end result is that you will discover things that impact your support costs, the cost of procedures, reliability, and even the cost of manufacturing.

And what appears to work in small quantities will meet the law of large numbers. You will discover new failure mechanisms at hundreds, thousands, and tens of thousands of deployments that didn't show up at all in smaller quantities.

What to get right:

• Design for manufacturing (DFM) - Engineering choices that enable efficient production
• Supply chain resilience - Identifying and qualifying backup suppliers for critical components
• Process validation - Demonstrating your manufacturing process reliably produces devices meeting specifications
• Yield and reliability - Understanding failure modes before they become field complaints

The transition from engineering-built prototypes to manufacturing-built production units often takes longer than founders expect. Custom tooling, process development, and supplier qualification can add 6-12 months to your timeline. Factor this into your regulatory and commercial planning.

Funding Your MedTech Startup: Strategies That Work in 2026

The Medtech Funding Lifecycle

Medtech funding follows a milestone-driven trajectory:

The key is matching your raise to specific milestones that increase the value of your company. Raise enough to hit the next one—plus buffer, because everything takes longer than expected.

The MedTech Milestone Matrix

The exact expectations for fundraising will vary depending on the regulatory path for your device. A 510(k) has a very different set of expectations from a Class III medical device. Some allowances should also be made for the significant variation in the definitions of the various fundraising stages. However, your fundraising milestones will look something like this:

If your regulatory milestones are behind your funding milestones, you're likely burning cash on the wrong priorities. If your team milestones lag both, you're missing the expertise to execute.

Who Invests in Medtech

The medtech investor landscape has bifurcated. Specialized funds dominate early-stage technical device companies, while generalist mega-funds increasingly drive late-stage digital health rounds. Understanding where you fit determines whom to target. See the 2026 MedTech VC Rankings for ranked tables and deal data.

Specialist Healthcare VCs

• Vensana Capital, ShangBay Capital, Catalyst Health Ventures, BioVentures MedTech — focused almost exclusively on medical devices
• OrbiMed, NEA, Third Rock Ventures, Versant Ventures — broader life sciences but deep medtech expertise
• Deep sector knowledge and regulatory pattern recognition, but high bar for entry
• Typically lead Seed through Series B for device companies

Generalist Mega-Funds

• General Catalyst, Andreessen Horowitz (a16z), Kleiner Perkins, Khosla Ventures — increasingly active in healthcare
• In 2025, General Catalyst deployed ~$839M across medtech and digital health, ranking as the top investor by capital deployed
• Bring massive follow-on capacity and platform resources, but may lack device-specific regulatory expertise
• Tend to favor software-heavy, AI-driven health companies over traditional hardware plays

Corporate Venture Arms

• Johnson & Johnson Innovation, Medtronic, Boston Scientific
• Strategic value beyond capital — technical validation, distribution, and regulatory insight
• May provide pathway to acquisition, but be aware of strategic strings attached

Seed and Accelerator Investors

• Y Combinator produced 20+ health and medtech startups in 2025 alone, including BillionToOne's $120K seed → $2.7B IPO — 1,600x valuation growth in eight years
• MedTech Innovator, JLABS, and disease-specific accelerators provide non-dilutive or low-dilution entry points
• Angel investors and family offices increasingly active; look for angels with healthcare operating experience

Non-Dilutive Funding: Grants and Government Programs

Non-dilutive capital is especially valuable in early-stage medtech, where every point of equity matters and development timelines are long.

• SBIR/STTR grants - Federal programs specifically designed for small business R&D. Phase I awards typically range from $150K-$275K; Phase II from $500K-$1.5M. Competition has intensified and current funding levels are under pressure, but the non-dilutive nature makes them worth pursuing.
• State economic development grants - Many states offer grants, tax credits, or subsidized lab space for life sciences companies. Programs vary widely by state—research your local options.
• Foundation grants - Disease-specific foundations (e.g., American Heart Association, Michael J. Fox Foundation) fund device development in their therapeutic areas. Often overlooked by founders focused on VC.
• Competition prize money - Programs like MedTech Innovator and various university competitions provide both capital and visibility.

The application effort is significant, but landing a $1M SBIR grant preserves equity that could be worth 10x that at exit.

Practical Fundraising Tactics

What works when raising in a tough market:

1. Talk to 100 investors - This is not an exaggeration; fundraising is a numbers game. Your hit rate will be low, so volume matters.
2. Target the right investors - Match sector focus, stage preference, and check size. Use Crunchbase or PitchBook to research who's actively investing in your space.
3. Create FOMO - Scarcity and momentum drive investment decisions. Signal that the round is moving and allocation is limited.
4. Get the lead - As Sal Braico puts it, "If you don't have a lead, you don't have anything." VCs who say "come back when you have a lead" are not committed. Once you have a lead, the rest fills quickly.
5. Send monthly updates - Keep potential investors warm with consistent communication, even when you're not actively raising.

The fundraising timeline reality:

Expect 6-12 months from first pitch to closed round. The process typically follows this pattern:

• Months 1-2: Initial meetings, refining pitch based on feedback
• Months 3-4: Second meetings with interested parties, due diligence begins
• Months 5-6: Term sheet negotiations, partner meetings
• Months 7-8: Legal documentation, final close

Many founders underestimate how long fundraising takes, especially for first-time founders without established relationships. Start earlier than you think you need to.

What investors are really asking:

• "Why will this work?" → Clinical and technical validation
• "Why now?" → Market timing and urgency
• "Why you?" → Team capability and commitment
• "Why this much?" → Capital efficiency and milestone clarity
• "How do I get my money back (and more)?" → Exit strategy and comparable transactions

The exit environment has improved. After a two-year drought, 2025 saw 13 medtech and digital health IPOs raising over $8.5 billion—including Medline's $6.26B offering, the largest U.S. IPO of any sector in 2025. M&A activity surged to $97.6 billion, up from $58.2 billion in 2024. This matters for fundraising because investors need to believe there's a realistic path to liquidity. A reopened IPO window and active acquirers make that case easier to make.

See Fundraising in a Difficult Capital Raising Environment for detailed tactics from a founder who's raised through three economic downturns.

Due Diligence Preparation

Investors, like acquirers, will run a due diligence examination on your company as part of their fiduciary duty to their institution or investors (e.g., limited partners). Investors want to demonstrate that your business isn't fraudulent, you're not incompetent, and that your business fits the parameters of their investment thesis. Most of all, they want to believe your startup is capable of succeeding in a way that returns incredible riches to them.

Be prepared with:

A data room containing:

• Corporate documents (incorporation, bylaws, cap table)
• Financial statements and projections
• Regulatory strategy documentation
• IP portfolio (patents, trademarks, trade secrets)
• Key contracts (suppliers, customers, partners)
• Team information (resumes, org chart, employment agreements)

Answers to common due diligence questions:

• What's your path to regulatory approval and timeline?
• What clinical evidence do you have or plan to generate?
• Who are your key competitors and how do you differentiate?
• What's your reimbursement strategy?
• What are the biggest risks and how are you mitigating them?

The companies that close fastest are the ones with clean documentation and clear answers ready. Sloppy materials signal sloppy operations—and investors notice.

Building the Right Team and Advisory Board

Essential Roles for Early-Stage MedTech

Your earliest employees set the pace and blaze the trail for the later ones. It's important not just to have the right skills, but also an approach to work compatible with a startup. Some people just can't handle the less-structured and more self-driven work style required in an early-stage startup.

The Milestone Matrix above shows when each function matters — here's what each one actually does. The specific roles you need depend on your stage and device type, but you can't skip these functions:

Technical Leadership

• Engineering/R&D lead with medical device experience
• Understanding of design controls and documentation requirements

Regulatory Affairs

• Even if outsourced initially, you need regulatory strategy input early
• This role carries the responsibility for navigating the submission process, and managing regulatory relationships.

Quality

• Responsible for QMS development and maintenance
• Ensures proper operation of the QMS, including audits
• Oversees compliance with applicable standards
• Often combined with regulatory in early stages

Clinical

• Medical director or clinical advisor
• Key opinion leader (KOL) relationships in your therapeutic area

Commercial (as you approach market)

• Understanding of hospital purchasing, GPOs, and IDNs
• Reimbursement and health economics expertise

Advisory Board Composition

A well-constructed advisory board fills expertise gaps and opens doors. Consider:

• Former FDA reviewer - Insight into how the agency thinks
• KOL in your therapeutic area - Clinical credibility and trial site access
• Successful medtech founder/executive - Pattern recognition and operational wisdom
• Reimbursement specialist - Navigate payer landscape and coding
• Industry veteran with exit experience - What acquirers look for

Board of Directors vs. Advisory Board

These serve different functions:

Board of Directors

• Fiduciary responsibility to shareholders
• Governance, major decisions, CEO oversight
• Typically includes investors, CEO, and independents
• Compensated with equity; significant time commitment

Advisory Board

• No fiduciary duty; advisory only
• Domain expertise and network access
• Flexible engagement (monthly calls, quarterly meetings)
• Smaller equity grants; less time commitment

Attracting and Compensating Advisors

For early-stage companies, advisor equity typically ranges from 0.1% to 0.5%, vesting over 2-4 years. More important than the specific number is:

• Clear expectations - Define the ask upfront (hours per month, specific deliverables)
• Value alignment - Advisors should believe in your mission
• Mutual benefit - What do they get beyond equity? Learning, network, impact?

For more on building effective clinical partnerships, see Partnering with MDs as an Industry.

A note on founding teams: The best early teams I've seen blend technical depth (engineering, science) with domain experience (clinical, regulatory, commercial). Pure technologists underestimate the non-technical complexity. Pure commercial operators underestimate the engineering challenges. The founders who figure this out early—and have the self-awareness to hire for their own gaps—tend to be the ones who make it.

Accelerators and Support Programs Worth Considering

Startup accelerators make up a special class of investors who provide support in addition to an investment. The right accelerator can compress timelines and open doors.

Accelerators tend to focus on early-stage companies, when advice is more general and can have a larger impact. The best accelerators can make introductions to great employee candidates, subject matter experts, potential partners, and to your next round of funding.

Y Combinator, for instance, has invested in a number of MedTech companies that have had good exits.

If you don't have experience taking a MedTech business from zero to the commercial stage, the right accelerator can do exactly what it says on the tin: give you a boost for a better chance at a meaningful exit.

What to evaluate before applying:

• Regulatory support - Do they understand FDA/CE pathways, or is their expertise primarily in software? A program that can't help you navigate device classification isn't worth the time.
• Relevant mentors - Are advisors experienced in your specific domain? General startup advice doesn't transfer cleanly to medtech.
• Capital connections - What's their track record of portfolio company fundraising? Ask for references from alumni at your stage.
• Equity cost vs. value - Programs range from zero equity (MedTech Innovator, JLABS) to 7% (Y Combinator). Non-dilutive options like the EIC Accelerator in Europe (up to €2.5M grant + €15M equity) are worth the rigorous application process.
• Time commitment - Can you afford three to six months of divided attention? For hardware companies deep in design controls, the distraction cost is real.

Case Studies: MedTech Startups That Got It Right

Tempus: From Startup to Precision Medicine Leader

Tempus built an AI-enabled platform for precision medicine, reaching a $6B+ valuation and NASDAQ IPO in June 2024. What stands out about Tempus is the data moat: proprietary clinical and molecular datasets that competitors can't easily replicate. They built a platform with multiple revenue streams (diagnostics, data licensing, clinical trial matching) that becomes more valuable with each patient sample processed. With $411M+ raised, they had the capital to execute a long-term vision, and the regulatory sophistication to navigate CLIA/CAP lab requirements alongside FDA device submissions.

CMR Surgical: Scaling Surgical Robotics Globally

CMR Surgical's Versius robot is a smart example of international regulatory sequencing. As a UK-based company, they got CE mark first, then pursued FDA—generating clinical data and commercial proof points in Europe that strengthened their U.S. pathway. With $200M+ raised, they capitalized for manufacturing scale before demand materialized. Their modular, smaller system architecture directly challenges Intuitive's da Vinci dominance, and their hospital relationships extend beyond device sales into training and procedure optimization.

Abridge: AI-Powered Clinical Documentation at Scale

Abridge built an AI platform that generates structured clinical notes from patient-physician conversations, reaching a $5.3B valuation after a $300M Series E in mid-2025—doubling its valuation in just four months. They found a problem physicians desperately wanted solved: documentation burden is a top driver of clinician burnout. Abridge landed major health system contracts (UPMC, UCI Health, Yale) by demonstrating measurable time savings, and made a smart regulatory move by positioning as a clinical workflow tool rather than a diagnostic device—simplifying their path while delivering clear clinical value. They rode the generative AI wave, but with genuine clinical validation behind it.

Abridge is a reminder that medtech success doesn't always require a Class II/III device pathway. If you can find where technology reduces real friction in clinical workflows—and prove it at scale—the market will respond.

Owlet: A Cautionary Tale of Regulatory Missteps

Owlet's Smart Sock, a consumer baby monitoring device, illustrates the cost of regulatory miscalculation:

• Initial approach - Marketed as a "wellness device" to avoid FDA clearance
• FDA warning letter (2021) - Agency determined the device made medical claims requiring clearance
• Business impact - $23 million contract revenue adjustment, halted sales, stock price collapse
• Resolution - Two years to obtain De Novo authorization for a redesigned "Dream Sock"

The lesson: regulatory strategy isn't something to figure out later. As covered in Regulatory Due Diligence 101, even with updated wellness guidance, disclaimers rarely protect devices that monitor health conditions with alerts or thresholds.

Lessons from Successful Exits

Recent major acquisitions reveal what acquirers value:

• Stryker/Inari Medical ($4.9B, 2025) - Category leadership in venous thromboembolism. Inari had created a new treatment category with strong clinical data and growing commercial traction.
• Elevance/CareBridge ($2.7B in ~5 years) - Rapid scaling of home-based care model. Demonstrated unit economics and payer value proposition.
• Boston Scientific/Silk Road Medical ($1.26B) - Differentiated technology in carotid disease with clear clinical advantages over existing approaches.
• Abbott/Cardiovascular Systems ($890M) - Complementary technology filling a gap in acquirer's product portfolio.

The 2025 IPO window added public-market exits to the mix:

• BillionToOne ($314M IPO, Nov 2025) - Molecular diagnostics company that went from Y Combinator's $120K seed check to a $2.7B IPO in eight years, briefly exceeding $6B market cap at its November peak.
• HeartFlow ($316.7M IPO, Aug 2025) - AI-powered cardiac diagnostics surged 47% on its first trading day, validating the market for computational diagnostics.
• Kestra Medical ($202M IPO, Mar 2025) - AI-enabled wearable defibrillator reached $1.4B market cap by year-end. Hardware companies with a strong AI angle are getting noticed.

Common threads across successful exits:

1. Clear clinical differentiation - Not "better" in a slide deck, but better in a way that shows up in clinical data
2. Strong IP position - Patents that make it expensive for others to compete
3. Established commercial traction - Revenue and reimbursement proof, beyond regulatory clearance alone
4. Strategic fit - Acquirer can see how the technology enhances their existing business
5. Clean regulatory history - No warning letters, recalls, or ongoing compliance issues

Finding the Right Advisor

When Founders Need Advisory Support Most

The moments where outside perspective matters most:

• Regulatory pathway decisions - Before you lock in a strategy that's hard to reverse
• Fundraising preparation - Getting your story and materials investor-ready
• Clinical trial design - Before spending millions on studies that may not support approval
• Commercialization planning - Before you hire a sales team and sign distributor contracts
• Pivot decisions - When the original plan isn't working; see Adapt to Thrive: The Role of Pivoting in Startups

What to Look for in a MedTech Advisor

Relevant regulatory experience

• Have they guided devices through your specific pathway?
• Do they have relationships at FDA?

Industry network

• Can they make introductions to investors, acquirers, KOLs?
• Are they known and respected in the community?

Successful exits

• Have they been through the full journey before?
• Do they understand what it takes to reach an outcome?

Stage-appropriate experience

• Big company executives don't always translate to startup environments
• Look for adaptability and hands-on willingness

Red Flags When Evaluating Advisory Relationships

• Generic advice - If the guidance could apply to any company, it's not valuable
• No device-specific experience - Healthcare ≠ medtech; software ≠ hardware
• Misaligned incentives - Advisors who push you toward their preferred vendors or investors
• Overcommitment - Advisors on too many boards can't give you real attention
• No skin in the game - Pure cash compensation without equity suggests low commitment

Conclusion

The 75% failure rate isn't a law of nature. Companies fail for identifiable, preventable reasons—bad sequencing, wrong investors, missing expertise, or simply running out of time before hitting the right milestones.

The founders I've watched succeed tend to share a few traits: they know their burn rate to the dollar, they figure out their regulatory pathway before they build, they validate with customer commitment rather than praise, and they surround themselves with people who've done it before. The original plan rarely survives contact with reality, but the best founders recognize when to pivot and when to persevere.

If you're navigating these challenges now, here's where to start: take the Milestone Matrix above and map where you actually are against where your funding and team milestones say you should be. If there's a gap — and there usually is — that's your most urgent problem. For help closing it, reach out directly or meet us at the next MedTech Connect Summit. I built MedTech Connect because I love helping these companies succeed, and the industry needs more of them.